Return to homepagePandemic Pact

ProTreat: an adaptive and rapid implementation trial of novel therapies to prevent and treat COVID19 infection in high risk cancer patients

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA85493

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $1,497,253.08

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Research Location

    Australia

  • Lead Research Institution

    University of Melbourne

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Individuals with multimorbidity, Other

  • Occupations of Interest

    Unspecified

Abstract

Cancer patients are likely to have more severe COVID and need hospital, ICU or die than the general population. Risk of drug reactions will stop them entering other trials.This trial has many points where a patient could join: preventing COVID with antivirus nose spray; higher dose after COVID exposure; treatment of moderate COVID; treatment for impending severe COVID. Each will be compared to inactive treatment. Results will be continually checked to see if the study should stop or be adjusted.